UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus
October 22, 2021 -- UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21.
The efficacy and safety of bimekizumab have not been established. Bimekizumab is an investigational product and not approved by the U.S. Food and Drug Administration (FDA). It is currently under review by the U.S. FDA for the treatment of moderate to severe plaque psoriasis in adults.
About the Studies†
While the number of therapies available for the treatment of plaque psoriasis has increased over the last 5 to 10 years, data from head-to-head comparisons are limited.1 To address this limitation, UCB conducted an NMA. While it does not replace head-to-head clinical trials, it can facilitate the comparison of multiple treatments by simultaneously analyzing the direct evidence of treatment comparisons and also indirect comparisons of treatments through a common comparator.2 Results from the NMA were presented at the International Society of Pharmacoeconomic Research (ISPOR), May 17-20, 2021.3
NNT was also calculated as part of the NMA analysis, which is an analytical approach often used in immunology to provide information on the relative benefit of therapies. It refers to the number of individuals that need to be treated with a given therapy in order to achieve the desired outcome in an additional individual. An ideal NNT is 1, indicating that only one patient needs to be treated to receive an additional benefit. As NNT increases, the less effective the intervention will be. Indirect comparisons produced from NMAs and NNTs do not imply superiority, nor do they replace randomized clinical trials. These data do not assess safety and therefore, conclusions regarding safety of any therapeutic agent cannot be made.
The objective of the analysis was to assess the NNT to achieve completely clear skin (PASI 100) or almost clear skin (PASI 90) in the short term (10-16 weeks) for bimekizumab and other approved biologics for the treatment of moderate to severe plaque psoriasis.4,5 The NNT values of biologic treatments compared to placebo to achieve one additional PASI 90 or PASI 100 response were calculated as the reciprocal of the corresponding absolute risk differences obtained from the NMA.4,5
Bimekizumab was Associated with the Lowest NNT to Achieve Completely Clear Skin or Almost Clear Skin within 16 Weeks
Using placebo as the reference group, the calculated NNT values were as follows:
NNT Values4,5† |
||
PASI 90* |
PASI 100 |
|
bimekizumab 320 mg |
1.22 |
1.74 |
risankizumab 150 mg |
1.40 |
2.26 |
brodalumab 210 mg |
1.42 |
2.30 |
ixekizumab 80 mg |
1.45 |
2.65 |
guselkumab 100 mg |
1.52 |
3.08 |
secukinumab 300 mg |
1.62 |
3.11 |
adalimumab 40 mg |
2.29 |
5.78 |
ustekinumab 45-90 mg |
2.30 |
5.72 |
tildrakizumab 100 mg |
2.80 |
7.61 |
etanercept 50 mg |
4.61 |
16.77 |
Posted: October 2021
Related articles
- UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa - November 20, 2024
- UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of Bimzelx (bimekizumab-bkzx) - October 14, 2024
- UCB Announces U.S. FDA Approvals for Bimzelx (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis - September 23, 2024
- FDA Approves Bimzelx (bimekizumab-bkzx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis - October 18, 2023
- UCB Provides Update on U.S. Regulatory Review of Bimekizumab - September 19, 2023
- UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab - June 26, 2023
- Update on U.S. FDA Review of Biologics License Application (BLA) for Bimekizumab - Complete Response Letter - May 13, 2022
Bimzelx (bimekizumab-bkzx) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.